Technology & Software Global On demand · 24-48h

Global Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Strategic Research Report

Global Diabetic Retinopathy (DR) Artificial Intelligence Scr…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market
$2932025
88%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Hardware, Software

By Application: Medical Institutions, Great Health Scene

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Airdoc Technology, Digital Diagnostics, Eyenuk, RetinaLyze System, Optomed, Sibionics Technology, Aeye Health, VUNO, Medimaging Integrated Solution, EyRIS (SELENA+), Vistel, RETINA-AI Health, Acer Medical

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 102 pages
Market size 2025
$293
Million USD
Forecast CAGR
88%
2025-2032
Forecast 2032
$24320.5
Projected
Gebieden
5
Asia Pacific · Latin America · MEA · Europe · North America

Overzicht

Scope of the Report

The global Diabetic Retinopathy (DR) Artificial Intelligence Screening System market size is predicted to grow from US$ 293 million in 2025 to US$ 22,790 million in 2032; it is expected to grow at a CAGR of 88.0% from 2026 to 2032.

Diabetic retinopathy (DR) represents a major cause of visual impairment in developed countries. The ever-growing incidence of DR and its complications necessitates new strategies to screen patients, prevent complications and optimize management. For this reason, DR is a major target of AI-based models, especially those that can be used for large-scale screening. AI models should recognize DR-related alterations, such as haemorrhages, exudates, cotton wool spots and neovascularization; and, starting from fundus images, establish the presence or absence of DR, and grade it according to the conventional DR grading scales.

Diabetes continues to rise throughout the United States and worldwide. Estimates show that the prevalence of diabetes mellitus will rise to 578 million people (10.2%) by the year 2030 and 700 million people (10.9%) by the year 2045. This increase in the prevalence of diabetes can also lead to a corresponding increase in diabetic complications, including nephropathy, cardiovascular disease, neuropathy, and retinopathy.

This report presents a comprehensive overview of the global Diabetic Retinopathy (DR) Artificial Intelligence Screening System market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Hardware
  • Software

Segment by Application

  • Medical Institutions
  • Great Health Scene

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Diabetic Retinopathy (DR) Artificial Intelligence Screening System market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Medical Institutions, Great Health Scene evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Diabetic Retinopathy (DR) Artificial Intelligence Screening System Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 88%
Regional growth momentum
Market share by segment
Key metrics
Base value
$293
2025
Forecast
$24320.5
2032
CAGR
88%
2025–2032
Gebieden
5
global
Key companies
Airdoc TechnologyDigital DiagnosticsEyenukRetinaLyze SystemOptomedSibionics TechnologyAeye HealthVUNO
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
HardwareSoftware
By Application
Medical InstitutionsGreat Health Scene

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Hardware
  • 3.1.3 Software
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Medical Institutions
  • 4.1.3 Great Health Scene
  • 4.1.4 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Airdoc Technology
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Digital Diagnostics
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Eyenuk
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 RetinaLyze System
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Optomed
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Sibionics Technology
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Aeye Health
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 VUNO
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Medimaging Integrated Solution
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 EyRIS (SELENA+)
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Vistel
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 RETINA-AI Health
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Acer Medical
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Diabetic Retinopathy (DR) Artificial Intelligence Screening System market?
The global Diabetic Retinopathy (DR) Artificial Intelligence Screening System market is estimated at US$ 293 million in 2025 (base year) and is projected to reach US$ 22.79 billion by 2032.
How fast is the Diabetic Retinopathy (DR) Artificial Intelligence Screening System market expected to grow?
The market is expected to grow at a CAGR of 88.0% from 2026 to 2032, expanding from US$ 293 million in 2025 to US$ 22.79 billion in 2032, roughly 77.8 times its base-year value.
What does the Diabetic Retinopathy (DR) Artificial Intelligence Screening System market cover?
Diabetic retinopathy (DR) represents a major cause of visual impairment in developed countries. The ever-growing incidence of DR and its complications necessitates new strategies to screen patients, prevent complications and optimize management. For this reason, DR is a major target of AI-based models, especially those that can be used for large-scale screening.
How is the Diabetic Retinopathy (DR) Artificial Intelligence Screening System market segmented by type?
By type, the market is segmented into Hardware and Software.
What are the key applications of Diabetic Retinopathy (DR) Artificial Intelligence Screening System?
Key applications covered include Medical Institutions and Great Health Scene.
Which companies are profiled in the Diabetic Retinopathy (DR) Artificial Intelligence Screening System market report?
Key players profiled include Airdoc Technology, Digital Diagnostics, Eyenuk, RetinaLyze System, Optomed, Sibionics Technology, Aeye Health and VUNO, among 13 companies covered in total.
What geographies does the Diabetic Retinopathy (DR) Artificial Intelligence Screening System market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
Who should buy the Diabetic Retinopathy (DR) Artificial Intelligence Screening System market report?
The report is intended for manufacturers and solution providers, distributors and end users in Medical Institutions and Great Health Scene, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Diabetic Retinopathy (DR) Artificial Intelligence Screening System market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from US$ 3.500,00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.